Non-Profit Trusted Source of Non-Commercial Health Information
The Original Voice of the American Academy of Anti-Aging, Preventative, and Regenerative Medicine
logo logo
Cloning Stem Cell Research

Stem Cells - The Hope and the Hype

12 years, 7 months ago

1685  0
Posted on Aug 02, 2006, 9 a.m. By Bill Freeman

When there's nothing else to prescribe, hope works like a drug. A quadriplegic patient tells herself it's not a matter of if they find a cure but when. Who's to say whether salvation is still 10 or 15 years away? After all, researchers have been injecting stem cells into paralyzed rats and watching their spinal cords mend. "Stem cells have already cured paralysis in animals," declared Christopher Reeve in a commercial he filmed a week before he died.

The debate is so politically loaded that it's tough to tell who's being straight about the real areas of progress and how breakthroughs can be achieved. TIME sorts it out
By NANCY GIBBS

When there's nothing else to prescribe, hope works like a drug. A quadriplegic patient tells herself it's not a matter of if they find a cure but when. Who's to say whether salvation is still 10 or 15 years away? After all, researchers have been injecting stem cells into paralyzed rats and watching their spinal cords mend. "Stem cells have already cured paralysis in animals," declared Christopher Reeve in a commercial he filmed a week before he died.

But what is the correct dose of hope when the diseases are dreadful and the prospects of cure distant? Last month, when President George W. Bush vetoed the bill that would have expanded funding for human embryonic-stem-cell (ESC) research, doctors got calls from patients with Parkinson's disease saying they weren't sure they could hang on for another year or two. The doctors could only reply that in the best-case scenario, cures are at least a decade away, that hope is no substitute for evidence, that stem-cell science is still in its infancy.

It is the nature of science to mix hope with hedging. It is the nature of politics to overpromise and mop up later. But the politics of stem-cell science is different. Opponents of ESC research—starting with Bush—argue that you can't destroy life in order to save it; supporters argue that an eight-cell embryo doesn't count as a human life in the first place—not when compared with the life it could help save. Opponents say the promise of embryo research has been oversold, and they point to the cures that have been derived from adult stem cells from bone marrow and umbilical cords; supporters retort that adult stem cells are still of limited use, and to fully realize their potential we would need to know more about how they operate—which we can learn only from studying leftover fertility-clinic embryos that would otherwise be thrown away.

Back and forth it goes, the politics driving the science, the science pushing back. Stem-cell research has joined global warming and evolution science as fields in which the very facts are put to a vote, a public spectacle in which data wrestle dogma. Scientists who are having surprising success with adult stem cells find their progress being used by activists to argue that embryo research is not just immoral but also unnecessary. But to those in the field, the only answer is to press ahead on all fronts. "There are camps for adult stem cells and embryonic stem cells," says Douglas Melton, a co-director of the Harvard Stem Cell Institute. "But these camps only exist in the political arena. There is no disagreement among scientists over the need to aggressively pursue both in order to solve important medical problems."

Trapped in all this are patients and voters who struggle to weigh the arguments because the science is dense and the values tangled. Somewhere between the flat-earthers who would gladly stop progress and the swashbucklers who disdain limits are people who approve of stem-cell research in general but get uneasy as we approach the ethical frontiers. Adult-stem-cell research is morally fine but clinically limiting, since only embryonic cells possess the power to replicate indefinitely and grow into any of more than 200 types of tissue. Extracting knowledge from embryos that would otherwise be wasted is one thing, but scientists admit that moving forward would require a much larger supply of fresh, healthy embryos than fertility clinics could ever provide. And once you start asking people about creating embryos for the purpose of experimenting on them, the support starts to slow down.

So where do things stand, five years after Bush provided the first federal funding but radically limited how it could be used?

How Red Tape Slowed the Science

In a prime-time speech from his texas ranch in August 2001, Bush announced that federal money could go to researchers working on ESC lines that scientists had already developed but no new lines could be created using federal funds. "There is at least one bright line," he declared. The speech was a political and scientific landmark. It gave Democrats that rare gift: a wedge issue that split Republicans and united Democrats, who declared themselves the party of progress. Five years later, with midterms looming, they hope to leverage the issue as evidence that they represent the reality-based community, running against the theocrats. States from Connecticut to California have tried to step in with enough funding to keep the labs going and slow the exodus of U.S. talent to countries like Singapore, Britain and Taiwan. Meanwhile, private biotech firms and research universities with other sources of funding are free to create and destroy as many embryos as they like, because they operate outside the regulations that follow public funds.

For scientists who choose to work with the approved "presidential" lines, the funding comes wrapped in frustration. Today there are only 21 viable lines, which limits genetic diversity. They are old, so they don't grow very well, and were cultured using methods that are outdated. What's more, the chromosomes undergo subtle changes over time, compromising the cells' ability to remain "normal." Back in the late '90s, when the lines were created, "we didn't know much about growing stem cells," says Kevin Eggan, principal faculty member at the Harvard Stem Cell Institute. "They can't do what the newer cell lines can do." Curt Civin, a cancer researcher at Johns Hopkins, has spent the past several years trying to differentiate the presidential lines into blood cells that could be used to treat leukemias and other blood-based cancers. But the age and quality of the cells have been a constant hindrance. "We want to study normal cells," he says. "We're working with Version 1.0. I'd like Version 3.3."

The presidential lines, scientists say, are wasting money as well as time. Larry Goldstein's lab at the University of California at San Diego is a life-size game of connect the dots. Each machine, cell dish, chemical and pretty much every major tool bears a colored dot, signaling to lab workers whether they can use the item for experiments that the government won't pay for. Goldstein's team is working on a cancer experiment that relies on a $200,000 piece of equipment. They can use either an approved cell line that will yield a less reliable result or a freshly created line that would require the purchase of another machine with private funds. "It's a ball and chain," Goldstein says. "It's goofy. Imagine if your kitchen was a mixture like that, where you can't use those pots with that soup." Congress tried to address the problem with its bill to allow funding for research on any leftover embryos donated by infertility patients. But even if Bush hadn't vetoed the bill, it wouldn't have solved the supply problems. One study estimated that at best, a couple hundred cell lines might be derived from leftover ivf embryos, which tend to be weaker than those implanted in patients. The very fact that they come from infertile couples may mean they are not typical, and the process of freezing and thawing is hard on delicate cells.

Solving a Problem Created New Ones

In the wake of bush's original order, Harvard decided to use private funding to develop about 100 new cell lines from fertility-clinic embryos, which it shares with researchers around the world. Scientists, desperate for variety, snap them up. "Not all embryonic-stem-cell lines are created equal," says Dr. Arnold Kriegstein, who runs the Institute for Regeneration Medicine at the University of California, San Francisco. "Some are more readily driven down a certain lineage, such as heart cells, while others more easily become nerve. We don't understand how it happens, but it does mean we need diversity."

At the same time, Harvard has opened another battleground in the search for cells. After exhaustive ethical review, its researchers announced this summer that they would develop new cell lines through somatic cell nuclear transfer, or therapeutic cloning. In this process, a cell from a patient with diabetes, for instance, is inserted into an unfertilized egg whose nucleus has been removed; then it is prodded into growing in a petri dish for a few days until its stem cells can be harvested. Unlike fertility-clinic embryos, these cells would match the patient's dna, so the body would be less likely to reject a transplant derived from them. Even more exciting for researchers, however, is that this technique can yield embryos that serve as the perfect disease in a dish, revealing how a disease unfolds from the very first hours.

The long-term promise is boundless, but the immediate barriers are high. The only people who claim to have succeeded in creating human-stem-cell lines through nuclear transfer were the South Korean researchers who turned out to be frauds. It will take much trial and error to master the process, but where do you get the human eggs needed for each attempt, particularly since researchers find it ethically inappropriate to reimburse donors for anything but expenses? And even if the technique for cloning embryos could be perfected, would Congress allow it to go on?

The Hunt for New Solutions

To get around political roadblocks, scientists are searching for another source of cells that is less ethically troublesome, ideally one that involves no embryo destruction at all. One approach is "altered nuclear transfer," in which a gene, known as cdx2, would be removed before the cell is fused with the egg. That would ensure that the embryo lives only long enough to produce stem cells and then dies. That strategy, promoted by Dr. William Hurlbut, a member of the President's Council on Bioethics, has its critics. Dr. Robert Lanza of biotech firm Advanced Cell Technology considers it unethical to deliberately create a crippled human embryo "not for a scientific or medical reason, but purely to address a religious issue." The most exciting new possibility doesn't go near embryos at all. Dr. Shinya Yamanaka of Kyoto University reported tantalizing success in taking an adult skin cell, exposing it to four growth factors in a petri dish and transforming it into an embryo-like entity that could produce stem cells—potentially sidestepping the entire debate over means and ends.

Even if scientists discover an ideal source of healthy cell lines, there is still much to learn about how to coax them into turning into the desired kind of tissue. Parkinson's patients suffering from tremors caused by damaged nerves could benefit from replacement neurons, while diabetics who can't produce insulin could control their blood sugar with new pancreatic islet cells. But so far, no human ESCs have been differentiated reliably enough that they could be safely transplanted into people, although animal studies with human cells are under way. Not surprisingly, the groups closest to human trials are in the biotech industry, which operates without government funds. Geron claims it is close to filing for permission to conduct the first human trials relying on ESC-based therapy. It is using stem cells to create oligodendroglial progenitor cells, which produce neurons and provide myelin insulation for the long fingers that extend out from the body of a nerve cell. Lanza's group is also close to filing for fda permission to begin clinical trials on three cell-based therapies: one for macular degeneration, one for repairing heart muscle and another for regenerating damaged skin. Not to to be outdone, the academic groups are just a few steps behind. Lorenz Studer at Memorial Sloan-Kettering Cancer Center in New York City has been able to differentiate ESCs into just about every cell type affected by Parkinson's disease and has transplanted them into rats and improved their mobility. Next, he plans to inject the cells into monkeys.

The Risks on the New Frontier

But the closer scientists come to human trials, the more concerned the fda will be with ensuring patient safety. The government will look at how the cells were grown and whether there would be risk of contamination from animal products used in the process. Regulators want data on how the cells will behave in the human body. Stem cells have shown a dismaying talent for turning into tumors. Will they migrate into unwanted areas? No one knows. You can't find out for sure until you test in humans, but it's hard to test in humans until you can be reasonably sure you won't harm them in the process. When human trials finally begin, there's no method for precisely determining whether the transplanted stem cells are functioning correctly. "If we transplanted cells to regenerate a pancreas," says Owen Witte, director of ucla's Institute for Stem Cell Biology and Medicine, "we can measure in your blood if you're producing insulin, but we can't see whether the cells have grown or evaluate whether they might grow into a tumor." So scientists are seeking to develop marking systems that let them trace a transplant's performance.

The Promise and Pitfalls of Adult Cells

Even as scientists press ahead with embryo research, exciting news has come from the least controversial sources: the stem cells in umbilical-cord blood and placentas, and even in fully formed adult organs. While not as flexible as embryonic cells, cord and placental cells have proved more valuable than scientists initially hoped. Although about 90% of cord-blood stem cells are precursors for blood and immune cells, the remaining 10% give rise to liver, heart-muscle and brain cells and more. Over the past five years, cord-blood transplants have become an increasingly popular alternative to bone-marrow transplants for blood disorders, particularly when a bone-marrow match can't be found.

If you want to lean out over the edges of science and marvel at what is now possible, visit Dr. Joanne Kurtzberg's program at Duke University Medical Center. Children with blood diseases that were almost certainly fatal a decade ago have got cord-blood transplants that essentially cure them. Now she and her team are taking a more targeted approach by attempting to differentiate cord-blood cells to address heart, brain and liver defects. "I think cord-blood cells have a lot of promise for tissue repair and regeneration," says Kurtzberg. "But I think it will take 10 to 20 years."

Less plastic than cord-blood cells are adult stem cells, which until recently researchers thought couldn't do much more than regenerate cell types that reflected the stem cells' origin—blood and immune cells from bone marrow, for example. Even so, some scientists believe adult stem cells may prove to be a powerful source of therapies. "In some cases, you may not want to go all the way back to embryonic stem cells," says Kurtzberg. "You may want something more specific or less likely to stray. You wouldn't want to put a cell in the brain and find out later that it turned into bone."

Researchers in Thailand have taken stem cells from the blood of cardiac patients, grown the cells in a lab and reinjected them into patients' hearts, where they set about repairing damage. Two ucla researchers last week published a study demonstrating that they could transform adult stem cells from fat tissue into smooth-muscle cells, which assist in the function of numerous organs. Welcome as the advances are, the subject of adult stem cells is highly political and invites a conflation of real hopes and false ones. "There are papers that have claimed broad uses for certain adult stem cells, and some people say that is sufficient cause to not work on embryonic stem cells," Witte says. "Many of those claims were overblown."

Even the true believers among scientists, however, dispute eager politicians who have called for a Manhattan Project approach to research. "I hate to say it, but biology is more complicated than splitting the atom," Witte says. "The physicists on the Manhattan Project knew what they needed to accomplish and how to measure it. In biology, we're codeveloping our measurement tools and our outcome tools at the same time." Indeed, a massive centralized effort controlled by the Federal Government could do more harm than good. The key is to have the broadest cross section of scientists possible working across the field. When it comes to such an impossibly complicated matter as stem cells, the best role for legislators and Presidents may be neither to steer the science nor to stall it but to stand aside and let it breathe.

Read Full Story

Subscribe to our Newsletter

WorldHealth Videos

WorldHealth Sponsors